Daridorexant was associated with improvements in both insomnia and comorbid nocturia in adults aged 55 years and older.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic ...

The maximum Quviviq (daridorexant) dosage for insomnia is 50 mg daily. Specific dosages may vary depending on factors like your individual health and other medications you may be taking.

Morningstar brands and products Company Portfolio ...

Nxera Pharma Co., Ltd. announces that it has entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. (Holling) for daridorexant in Taiwan. Daridorexant is an oral dual ...

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic ...